Author's Accepted Manuscript

Ablative Therapies for Early-Stage Kidney Cancer and the Evolving Role of the Urologist

Andrew T. Lenis, MD, MS, Hung-Jui Tan, MD, MSHPM, Joshua A. Halpern, MD, Aaron A. Laviana, MD, Brian Shuch, MD, Jim C. Hu, MD, MPH



PII: S2352-0779(16)30178-9 DOI: 10.1016/j.urpr.2016.04.004

Reference: URPR 202

To appear in: *Urology Practice* Accepted Date: 19 April 2016

Please cite this article as: Lenis AT, Tan H-J, Halpern JA, Laviana AA, Shuch B, Hu JC, Ablative Therapies for Early-Stage Kidney Cancer and the Evolving Role of the Urologist, *Urology Practice* (2016), doi: 10.1016/j.urpr.2016.04.004.

DISCLAIMER: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our subscribers we are providing this early version of the article. The paper will be copy edited and typeset, and proof will be reviewed before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to The Journal pertain.

All press releases and the articles they feature are under strict embargo until uncorrected proof of the article becomes available online. We will provide journalists and editors with full-text copies of the articles in question prior to the embargo date so that stories can be adequately researched and written. The standard embargo time is 12:01 AM ET on that date.

ACCEPTED MANUSCRIPT

ABLATIVE THERAPIES FOR EARLY-STAGE KIDNEY CANCER AND THE EVOLVING ROLE OF THE UROLOGIST

Andrew T. Lenis MD, MS¹; Hung-Jui Tan MD, MSHPM¹; Joshua A. Halpern MD²; Aaron A. Laviana MD¹; Brian Shuch, MD³; Jim C. Hu, MD, MPH²

FUNDING SOURCE: This research was supported by the American Cancer Society Postdoctoral Fellowship Program (126217-PF-14-028-01-CPHPS to HT)

Abstract Word Count: 246 **Manuscript Word Count:** 2499

References: 30 Text pages: 15 Tables: 1 Figures: 4

Running Title: Ablation practice patterns for early-stage kidney cancer

This study used the linked SEER-Medicare database. The interpretation and reporting of these data are the sole responsibility of the authors. The authors acknowledge the efforts of the Applied Research Program, NCI; the Office of Research, Development and Information, CMS; Information Management Services (IMS), Inc.; and the Surveillance, Epidemiology, and End Results (SEER) Program tumor registries in the creation of the SEER-Medicare database.

Corresponding author: Hung-Jui Tan, MD, MS University of California, Los Angeles 300 Stein Plaza, 3rd Floor Los Angeles, CA 90095

Phone: (310) 794-8659 Fax: (310) 794-8653

Email: htan@mednet.ucla.edu

Keywords (**MeSH Terms**): kidney; ablation techniques; kidney neoplasms; treatment outcome; carcinoma, renal cell

¹Department of Urology, David Geffen School of Medicine at UCLA, Los Angeles, California

²Department of Urology, Weill Cornell Medical College, New York, New York

³Department of Urology and Radiology, Yale School of Medicine, New Haven, Connecticut

Download English Version:

https://daneshyari.com/en/article/8830396

Download Persian Version:

https://daneshyari.com/article/8830396

<u>Daneshyari.com</u>